OBJECTIVE: To evaluate levels of lipoprotein(a) in patients with primary antiphospholipid syndrome (PAPS) and its possible associations with clinical and laboratory features. METHODS: Transversal study with 46 (93.5% female) PAPS patients (Sapporo criteria). Demographic, clinical, drugs use, and antiphospholipid antibodies data were evaluated, as well as measurements of lipoprotein(a) serum fasting levels. RESULTS: Elevated levels of lipoprotein(a) ( > 30 mg/dL) were observed in 43.5% of PAPS patients, with a mean of 42 ± 43.5 mg/dL. A comparison between patients with lipoprotein(a) higher than 30 mg/dL and those with < 30 mg/dL did not show any differences regarding demographics (age, gender, white race, weight, height, body mass index), diseases features (arterial, venous or obstetric events, thrombocytopenia), cardiovascular manifestations (acute myocardial infarct, angina, stroke), comorbidities, life style (physical activity, smoking), drugs use (corticosteroids, statins, chloroquine), as well as the frequency of positivity of antiphospholipid antibodies. CONCLUSION: PAPS patients had a high frequency of increased levels of lipoprotein(a), however there was no association of this abnormality with the clinical and laboratorial features herein studied.
lipoprotein(a); Lp(a); antiphospholipid syndrome; antiphospholipid antibodies
